Logo

CVKD

Cadrenal Therapeutics, Inc. Common Stock

CVKD

Cadrenal Therapeutics, Inc. Common Stock • NASDAQ
$9.39 ▲ 0.08% (+0.01)
Market Cap $19.48 M
52w High $22.90
52w Low $8.74
Dividend Yield 0%
P/E -1.08
Volume 10.26K
Outstanding Shares 2.08M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $2.733M ▼ $-2.686M ▲ 0% $-1.31 ▲ $-2.685M ▲
Q2-2025 $0 $3.734M ▼ $-3.667M ▲ 0% $-1.87 ▲ $-3.734M ▲
Q1-2025 $0 $3.922M ▼ $-3.845M ▲ 0% $-2.09 ▲ $-3.84M ▲
Q4-2024 $0 $4.278M ▲ $-4.187M ▼ 0% $-2.75 ▼ $-4.187M ▼
Q3-2024 $0 $2.46M $-2.408M 0% $-2.18 $-2.407M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $3.86M ▼ $4.088M ▼ $1.353M ▼ $2.735M ▼
Q2-2025 $5.571M ▼ $5.978M ▼ $1.68M ▼ $4.299M ▼
Q1-2025 $7.336M ▼ $7.953M ▼ $1.84M ▼ $6.113M ▼
Q4-2024 $10.018M ▲ $10.124M ▲ $2.684M ▲ $7.44M ▲
Q3-2024 $4.364M $4.679M $1.267M $3.412M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.686M ▲ $-2.357M ▲ $-1.853K ▼ $648.355K ▼ $-1.711M ▲ $-2.359M ▲
Q2-2025 $-3.667M ▲ $-3.026M ▲ $0 ▲ $1.26M ▼ $-1.765M ▲ $-3.026M ▲
Q1-2025 $-3.845M ▲ $-4.649M ▼ $-3.251K ▲ $1.97M ▼ $-2.682M ▼ $-4.652M ▼
Q4-2024 $-4.187M ▼ $-1.791M ▲ $-6.537K ▼ $7.451M ▲ $5.654M ▲ $-1.797M ▲
Q3-2024 $-2.408M $-2.201M $0 $1.528M $-673.274K $-2.201M

Five-Year Company Overview

Income Statement

Income Statement Cadrenal is still a pure development‑stage biotech: it has no product revenue and its income statement is driven almost entirely by research and corporate expenses. Losses are currently small in absolute dollar terms but effectively 100% of activity, since there is no offsetting sales. Earnings per share look heavily negative mostly because the company is tiny and has recently adjusted its share count via a reverse split, not because of a large operating business. Overall, the income statement reflects a classic early‑stage biotech profile: all cost, no revenue yet, and results that will likely stay volatile and dependent on trial spending and financing events rather than on commercial performance.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a small base of assets and those assets largely sitting in cash. There is no financial debt, which reduces interest burden but also signals that the company relies primarily on equity financing. Shareholders’ equity is positive but thin, leaving little cushion if losses accelerate. In simple terms, the company appears clean but fragile: it is not weighed down by leverage, yet its asset base is minimal and its ability to fund long trials will hinge on raising more capital over time.

Cash Flow

Cash Flow Cash flows reflect a company that is spending to build future products rather than running a commercial operation today. Operating cash flow is negative as research, clinical planning, and corporate costs run ahead of any incoming cash from customers. Capital spending needs are low, so most cash use is tied directly to people, trials, and intellectual property. This pattern is typical for a clinical‑stage biotech but it also means the business is structurally dependent on periodic external funding; the key risk is how long existing cash can support the planned clinical program before another raise is needed.

Competitive Edge

Competitive Edge Cadrenal’s competitive position rests on a focused anticoagulation pipeline addressing patients who are poorly served by current therapies. Tecarfarin aims to improve on warfarin’s long‑standing weaknesses, particularly in complex patients such as those with severe kidney disease or mechanical heart devices, areas where newer blood thinners are often not suitable. Regulatory designations for rare conditions and a collaboration with a major device maker add credibility and potential future protection. At the same time, the company is small and operates in a field crowded with very large pharmaceutical competitors, so its long‑term position will depend heavily on clear clinical advantages, strong trial data, and its ability to secure partners or commercialization support.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Cadrenal’s story. Tecarfarin is designed to work like an older, well‑known drug but be processed differently by the body, aiming for more stable and predictable blood‑thinning, fewer interactions with other medicines, and less impact from genetic differences. The addition of frunexian, a Factor XIa inhibitor for hospital and acute use, and an oral follow‑on candidate broadens the platform into a newer class of anticoagulants that may offer protection from clots with less bleeding. The company’s R&D strategy is to focus on high‑risk, underserved patients and pursue orphan indications and accelerated regulatory paths. The upside is a clearer path to approval in tightly defined niches; the downside is heavy dependence on a small number of assets and the need for consistent funding and strong patent protection to carry these programs through late‑stage trials.

Summary

Cadrenal Therapeutics is an early, high‑risk, high‑uncertainty biotech centered entirely on a specialized anticoagulation pipeline. Financial statements show a very small, pre‑revenue company with modest ongoing losses, a cash‑heavy but thin balance sheet, and negative operating cash flow that will likely require further external financing. Strategically, the company is targeting difficult cardiovascular populations with meaningful unmet need and holds regulatory advantages and partnerships that support its scientific case. However, its future value is tightly tied to the success of a few clinical programs and its ability to maintain funding and intellectual property. This makes outcomes highly binary: progress in trials and regulatory discussions could be transformative, while setbacks or funding challenges could quickly strain the company’s limited financial base.

NEWS

November 19, 2025 · 8:00 AM UTC

Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award

Read more

November 10, 2025 · 9:00 AM UTC

Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Read more

September 29, 2025 · 4:30 PM UTC

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Read more

September 15, 2025 · 8:00 AM UTC

Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors

Read more